CA2967112C - Quinoline carboxamides for use in the treatment of leukemia - Google Patents
Quinoline carboxamides for use in the treatment of leukemia Download PDFInfo
- Publication number
- CA2967112C CA2967112C CA2967112A CA2967112A CA2967112C CA 2967112 C CA2967112 C CA 2967112C CA 2967112 A CA2967112 A CA 2967112A CA 2967112 A CA2967112 A CA 2967112A CA 2967112 C CA2967112 C CA 2967112C
- Authority
- CA
- Canada
- Prior art keywords
- leukemia
- pharmaceutically acceptable
- compound
- acceptable salt
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193776 | 2014-11-19 | ||
| EP14193776.3 | 2014-11-19 | ||
| PCT/EP2015/075769 WO2016078921A1 (en) | 2014-11-19 | 2015-11-05 | Quinoline carboxamides for use in the treatment of leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2967112A1 CA2967112A1 (en) | 2016-05-26 |
| CA2967112C true CA2967112C (en) | 2023-05-16 |
Family
ID=51951635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2967112A Active CA2967112C (en) | 2014-11-19 | 2015-11-05 | Quinoline carboxamides for use in the treatment of leukemia |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10300053B2 (enExample) |
| EP (1) | EP3180005B1 (enExample) |
| JP (1) | JP6715833B2 (enExample) |
| KR (1) | KR102525805B1 (enExample) |
| CN (1) | CN107072989B (enExample) |
| AU (1) | AU2015348778B2 (enExample) |
| BR (1) | BR112017009854B1 (enExample) |
| CA (1) | CA2967112C (enExample) |
| EA (1) | EA031643B1 (enExample) |
| ES (1) | ES2663836T3 (enExample) |
| IL (1) | IL252174B (enExample) |
| MX (1) | MX379401B (enExample) |
| NZ (1) | NZ732704A (enExample) |
| PL (1) | PL3180005T3 (enExample) |
| WO (1) | WO2016078921A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102978225B1 (ko) | 2020-03-03 | 2026-06-15 | 액티브 바이오테크 에이비 | 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염 |
| US20230293512A1 (en) | 2020-07-23 | 2023-09-21 | Erasmus University Medical Center Rotterdam | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| WO2022152902A1 (en) | 2021-01-18 | 2022-07-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| CN116887844A (zh) * | 2021-01-18 | 2023-10-13 | 活跃生物技术有限公司 | 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐 |
| KR20240012436A (ko) * | 2021-05-25 | 2024-01-29 | 액티브 바이오테크 에이비 | 복수의 타스퀴니모드 입자 및 그 용도 |
| CA3221689A1 (en) * | 2021-07-02 | 2023-01-05 | Hans Wannman | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| WO2012004338A1 (en) | 2010-07-09 | 2012-01-12 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| WO2015095833A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
-
2015
- 2015-11-05 BR BR112017009854-7A patent/BR112017009854B1/pt active IP Right Grant
- 2015-11-05 EA EA201791099A patent/EA031643B1/ru not_active IP Right Cessation
- 2015-11-05 KR KR1020177015989A patent/KR102525805B1/ko active Active
- 2015-11-05 US US15/525,086 patent/US10300053B2/en active Active
- 2015-11-05 WO PCT/EP2015/075769 patent/WO2016078921A1/en not_active Ceased
- 2015-11-05 PL PL15790143T patent/PL3180005T3/pl unknown
- 2015-11-05 ES ES15790143.0T patent/ES2663836T3/es active Active
- 2015-11-05 EP EP15790143.0A patent/EP3180005B1/en active Active
- 2015-11-05 JP JP2017525360A patent/JP6715833B2/ja active Active
- 2015-11-05 MX MX2017006110A patent/MX379401B/es unknown
- 2015-11-05 NZ NZ732704A patent/NZ732704A/en unknown
- 2015-11-05 CN CN201580062750.4A patent/CN107072989B/zh active Active
- 2015-11-05 CA CA2967112A patent/CA2967112C/en active Active
- 2015-11-05 AU AU2015348778A patent/AU2015348778B2/en active Active
-
2017
- 2017-05-09 IL IL252174A patent/IL252174B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US10300053B2 (en) | 2019-05-28 |
| KR102525805B1 (ko) | 2023-04-25 |
| US20170319568A1 (en) | 2017-11-09 |
| WO2016078921A1 (en) | 2016-05-26 |
| JP6715833B2 (ja) | 2020-07-01 |
| EP3180005A1 (en) | 2017-06-21 |
| MX2017006110A (es) | 2017-07-27 |
| BR112017009854B1 (pt) | 2022-08-23 |
| EA031643B1 (ru) | 2019-01-31 |
| CN107072989B (zh) | 2020-07-03 |
| IL252174B (en) | 2021-02-28 |
| JP2017534652A (ja) | 2017-11-24 |
| ES2663836T3 (es) | 2018-04-17 |
| NZ732704A (en) | 2022-01-28 |
| EP3180005B1 (en) | 2017-12-27 |
| CN107072989A (zh) | 2017-08-18 |
| IL252174A0 (en) | 2017-07-31 |
| PL3180005T3 (pl) | 2018-06-29 |
| MX379401B (es) | 2025-03-11 |
| BR112017009854A2 (pt) | 2018-01-16 |
| AU2015348778A1 (en) | 2017-06-29 |
| EA201791099A1 (ru) | 2017-10-31 |
| AU2015348778B2 (en) | 2020-12-24 |
| CA2967112A1 (en) | 2016-05-26 |
| KR20170083121A (ko) | 2017-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10300053B2 (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| JP7223998B2 (ja) | Ａｘｌ阻害剤を有効成分として含む固形がん治療剤 | |
| US10314836B2 (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| CN104436194B (zh) | 具有协同增效作用的抗癌组合物 | |
| CN117064897A (zh) | 用于治疗血液病的化合物和组合物 | |
| TW202019409A (zh) | Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或bcl-2抑制劑與chop聯合用藥的協同抗腫瘤作用 | |
| JP2017534652A5 (enExample) | ||
| HK1237658B (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| HK1237658A1 (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| HK1226643A1 (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| HK1226643B (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| CN112535686B (zh) | 激酶抑制剂的新用途 | |
| BR112017004947B1 (pt) | Uso de um composto ou sal farmaceuticamente aceitável | |
| AU2024306742A1 (en) | Quinoline carboxamides for use in the treatment of mpn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201015 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241028 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241028 |